Annukka Pasanen

List of Publications by Year
in descending order

38 papers	**763** citations	687363 **13** h-index	552781 **26** g-index
39 all docs	**39** docs citations	**39** times ranked	**1123** citing authors

#	Article	IF	Citations
1	Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade. Gynecologic Oncology, 2022, 164, 187-194.	1.4	6
2	Clinicopathologic vs. Molecular Integrated Prognostication of Endometrial Carcinoma by European Guidelines. Cancers, 2022, 14, 651.	3.7	9
3	TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma. Gynecologic Oncology, 2022, 165, 577-584.	1.4	8
4	Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis. Cancers, 2022, 14, 1348.	3.7	3
5	Histopathologic and Molecular Characterization of Uterine Leiomyomaâ€"like Inflammatory Myofibroblastic Tumor. American Journal of Surgical Pathology, 2022, 46, 1126-1136.	3.7	8
6	Mismatch repair protein and <i>MLH1</i> methylation status as predictors of response to adjuvant therapy in endometrial cancer. Cancer Medicine, 2021, 10, 1034-1042.	2.8	23
7	Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 471-479.	2.8	27
8	Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma. Cancers, 2021, 13, 3124.	3.7	8
9	Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. Nature, 2021, 596, 398-403.	27.8	53
10	Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma. PLoS ONE, 2021, 16, e0253472.	2.5	7
11	Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer. Pathology and Oncology Research, 2021, 27, 1609936.	1.9	4
12	Parity associates with chromosomal damage in uterine leiomyomas. Nature Communications, 2021, 12, 5448.	12.8	2
13	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. American Journal of Surgical Pathology, 2020, 44, 174-181.	3.7	52
14	3â€²RNA Sequencing Accurately Classifies Formalin-Fixed Paraffin-Embedded Uterine Leiomyomas. Cancers, 2020, 12, 3839.	3.7	9
15	Altered glycosylation of glycodelin in endometrial carcinoma. Laboratory Investigation, 2020, 100, 1014-1025.	3.7	16
16	Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Modern Pathology, 2020, 33, 1443-1452.	5.5	51
17	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLoS ONE, 2020, 15, e0242733.	2.5	12
18	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0

#	ARTICLE	IF	CITATIONS
19	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0
20	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0
21	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0
22	American Society of Anesthesiologists physical status score as a predictor of long-term outcome in women with endometrial cancer. International Journal of Gynecological Cancer, 2019, 29, 879-885.	2.5	5
23	Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecologic Oncology, 2018, 150, 92-98.	1.4	29
24	Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance. Modern Pathology, 2018, 31, 1291-1301.	5.5	25
25	<i>MED12</i> mutations and fumarate hydratase inactivation in uterine adenomyomas. Human Reproduction Open, 2018, 2018, hoy020.	5.4	5
26	Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. ELife, 2018, 7, .	6.0	58
27	Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort. Gynecologic Oncology, 2017, 144, 510-514.	1.4	13
28	Global metabolomic profiling of uterine leiomyomas. British Journal of Cancer, 2017, 117, 1855-1864.	6.4	29
29	Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas. Scientific Reports, 2017, 7, 1015.	3.3	44
30	Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker. International Journal of Gynecological Cancer, 2017, 27, 1318-1324.	2.5	11
31	L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecologic Oncology, 2017, 146, 615-622.	1.4	12
32	L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. International Journal of Gynecological Cancer, 2016, 26, 1465-1471.	2.5	30
33	Incidence of and risk factors for surgical site infections in women undergoing hysterectomy for endometrial carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 480-485.	2.8	5
34	Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1315-1320.	7.1	166
35	Abstract 436: Glycodelin expression in endometrial carcinoma. Cancer Research, 2016, 76, 436-436.	0.9	1
36	Abstract 120: Estrogen and progesterone receptor expression in different molecular uterine leiomyoma subclasses. , 2016, , .		0

#	Article	IF	Citations
37	Risk-stratification of endometrial carcinomas revisited: A combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease. Gynecologic Oncology, 2015, 137, 23-27.	1.4	24
38	Molecular classification of endometrial carcinoma: a clinically oriented review. Journal of Clinical Pathology, 0, , jclinpath-2022-208345.	2.0	8